Ramadan, Sherin
(2026)
Understanding Hereditary Spastic Paraplegia SPG9: developing models to test therapeutic interventions., [Dissertation thesis], Alma Mater Studiorum Università di Bologna.
Dottorato di ricerca in
Scienze mediche generali e scienze dei servizi, 38 Ciclo. DOI 10.48676/unibo/amsdottorato/13326.
Documenti full-text disponibili:
![Ramadan_Sherin_Tesi.pdf [thumbnail of Ramadan_Sherin_Tesi.pdf]](https://amsdottorato.unibo.it/style/images/fileicons/application_pdf.png) |
Documento PDF (English)
- Richiede un lettore di PDF come Xpdf o Adobe Acrobat Reader
Disponibile con Licenza: Salvo eventuali più ampie autorizzazioni dell'autore, la tesi può essere liberamente consultata e può essere effettuato il salvataggio e la stampa di una copia per fini strettamente personali di studio, di ricerca e di insegnamento, con espresso divieto di qualunque utilizzo direttamente o indirettamente commerciale. Ogni altro diritto sul materiale è riservato.
Download (5MB)
|
Abstract
Hereditary Spastic Paraplegias (HSPs) are a heterogeneous group of neurodegenerative disorders characterized by progressive spasticity and weakness of the lower limbs. Among them, Spastic Paraplegia type 9 (SPG9) is caused by pathogenic variants in ALDH18A1, which encodes the mitochondrial enzyme Δ1-pyrroline-5-carboxylate synthetase (P5CS). This enzyme catalyzes the first steps of glutamate conversion into intermediates involved in proline biosynthesis and the urea cycle. Alterations in ALDH18A1 are associated with a complex phenotype characterized by spastic paraplegia, congenital cataracts, persistent vomiting, amyotrophy, joint laxity, reduced plasma levels of citrulline, arginine, ornithine and proline, and hyperammonemia. The aim of this study was to characterize a cellular model of SPG9 based on fibroblasts derived from a patient carrying the pathogenic ALDH18A1 variant p.Val243Leu and to investigate potential therapeutic approaches based on amino acid supplementation and gene editing. Patient-derived and control fibroblasts were analyzed through fluorescence microscopy, flow cytometry, proliferation assays, transmission electron microscopy, western blotting, and assays evaluating reactive oxygen species (ROS) and ATP production. In addition, CRISPR-Cas9 and Cas12-mediated homology-directed repair (HDR) strategies were designed to correct the pathogenic variant. Patient fibroblasts exhibited significant morphological and functional alterations compared with controls. The p.Val243Leu variant impaired cellular proliferation, affected cell-cycle progression, increased oxidative stress, and reduced ATP production, indicating mitochondrial dysfunction and altered cellular homeostasis. Arginine supplementation partially rescued several disease-associated phenotypic features, suggesting a potential therapeutic benefit. Although precise correction of the mutation by HDR was not achieved with sufficient efficiency, the results highlight the potential of emerging genome-editing technologies for future therapeutic development. Overall, this study provides new insights into the molecular mechanisms underlying SPG9 and demonstrates that patient-derived fibroblasts represent a valuable in vitro model for investigating disease pathogenesis and evaluating novel therapeutic strategies.
Abstract
Hereditary Spastic Paraplegias (HSPs) are a heterogeneous group of neurodegenerative disorders characterized by progressive spasticity and weakness of the lower limbs. Among them, Spastic Paraplegia type 9 (SPG9) is caused by pathogenic variants in ALDH18A1, which encodes the mitochondrial enzyme Δ1-pyrroline-5-carboxylate synthetase (P5CS). This enzyme catalyzes the first steps of glutamate conversion into intermediates involved in proline biosynthesis and the urea cycle. Alterations in ALDH18A1 are associated with a complex phenotype characterized by spastic paraplegia, congenital cataracts, persistent vomiting, amyotrophy, joint laxity, reduced plasma levels of citrulline, arginine, ornithine and proline, and hyperammonemia. The aim of this study was to characterize a cellular model of SPG9 based on fibroblasts derived from a patient carrying the pathogenic ALDH18A1 variant p.Val243Leu and to investigate potential therapeutic approaches based on amino acid supplementation and gene editing. Patient-derived and control fibroblasts were analyzed through fluorescence microscopy, flow cytometry, proliferation assays, transmission electron microscopy, western blotting, and assays evaluating reactive oxygen species (ROS) and ATP production. In addition, CRISPR-Cas9 and Cas12-mediated homology-directed repair (HDR) strategies were designed to correct the pathogenic variant. Patient fibroblasts exhibited significant morphological and functional alterations compared with controls. The p.Val243Leu variant impaired cellular proliferation, affected cell-cycle progression, increased oxidative stress, and reduced ATP production, indicating mitochondrial dysfunction and altered cellular homeostasis. Arginine supplementation partially rescued several disease-associated phenotypic features, suggesting a potential therapeutic benefit. Although precise correction of the mutation by HDR was not achieved with sufficient efficiency, the results highlight the potential of emerging genome-editing technologies for future therapeutic development. Overall, this study provides new insights into the molecular mechanisms underlying SPG9 and demonstrates that patient-derived fibroblasts represent a valuable in vitro model for investigating disease pathogenesis and evaluating novel therapeutic strategies.
Tipologia del documento
Tesi di dottorato
Autore
Ramadan, Sherin
Supervisore
Co-supervisore
Dottorato di ricerca
Ciclo
38
Coordinatore
Settore disciplinare
Settore concorsuale
Parole chiave
Hereditary Spastic Paraplegia; SPG9; ALDH18A1; P5CS; Fibroblasts; Arginine Supplementation; Mitochondrial Dysfunction; Gene Editing; CRISPR-Cas9.
DOI
10.48676/unibo/amsdottorato/13326
Data di discussione
3 Luglio 2026
URI
Altri metadati
Tipologia del documento
Tesi di dottorato
Autore
Ramadan, Sherin
Supervisore
Co-supervisore
Dottorato di ricerca
Ciclo
38
Coordinatore
Settore disciplinare
Settore concorsuale
Parole chiave
Hereditary Spastic Paraplegia; SPG9; ALDH18A1; P5CS; Fibroblasts; Arginine Supplementation; Mitochondrial Dysfunction; Gene Editing; CRISPR-Cas9.
DOI
10.48676/unibo/amsdottorato/13326
Data di discussione
3 Luglio 2026
URI
Statistica sui download
Gestione del documento: